

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Raily Aesthetic Medicine International Holdings Limited**

**瑞麗醫美國際控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2135)**

### **PROFIT WARNING**

This announcement is made by the Company pursuant to Rule 13.09 of the Listing Rules and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the SFO.

The Board wishes to inform the shareholders of the Company and potential investors that, the Group is expected to record a loss attributable to the shareholders of the parent of approximately RMB5 million for the six months ended 30 June 2021.

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.**

This announcement is made by Raily Aesthetic Medicine International Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (the “**SFO**”).

The board of directors (the “**Board**”) of the Company wishes to inform the shareholders of the Company and potential investors that, based on the currently available preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2021 (the “**Unaudited Management Accounts**”):

- (i) the Board expects the Group to record a revenue of approximately RMB91 million for the six months ended 30 June 2021, representing a significant increase of approximately 54% as compared to the revenue of approximately RMB59 million in the same period last year and;

- (ii) the Board expects the Group to record a loss attributable to the shareholders of the parent of approximately RMB5 million for the six months ended 30 June 2021, representing a decrease of approximately 58% as compared to the loss attributable to the shareholders of the parent of approximately RMB12 million in the same period last year.

The Board considers that reasons for the significant increase in revenue and the decrease in loss recorded by the Group are as follows:

- i) Although various measures have been taken to control COVID-19 pandemic in the PRC, the pandemic still had an impact on the Group's operation. For example, the operation of Ruian Raily Medical Beauty Hospital Co., Ltd., a subsidiary of the Company, has been temporarily suspended for half a month in June 2021 due to the pandemic;
- ii) The Group increased promoting and marketing activities to increase customer flow and restore clients' enthusiasm for aesthetic surgery services so as to enhance the Group's brand awareness and prepare for sales in the second half;
- iii) The Group reduced the professional fee for the six months ended 30 June 2021 by RMB 5 million as compared to the same period last year and;
- iv) The proceeds raised from the listing of the Company's securities on the Stock Exchange of Hong Kong Limited are denominated in Hong Kong dollars, and incurred an exchange loss of approximately RMB1 million for the six months ended 30 June 2021.

The information contained in this announcement is only based on the preliminary assessment by the Company's management according to the Unaudited Management Accounts and with reference to the information currently available, which have not been finalized or independently reviewed by the Company's auditors or the audit committee, and are subject to amendments and adjustments where necessary. Shareholders and potential investors should refer to and review the interim results of the Company for the six months ended 30 June 2021, which are expected to be published in August 2021.

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board of  
**Raily Aesthetic Medicine International Holdings Limited**  
**Mr. Fu Haishu**  
*Chairman*

Hangzhou, the PRC, 2 August 2021

*As at the date of this announcement, the Board comprises Mr. Fu Haishu, Mr. Yu Kai and Mr. Song Jianliang as executive Directors; Mr. Xie Lijun and Ms. Fan Qirui as non-executive Directors; and Mr. Cao Dequan, Ms. Yang Xiaofen and Mr. Liu Teng as independent non-executive Directors.*